Αρχική World News FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or... World News FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Από Ogkologos - 25 Φεβρουαρίου, 2026 446 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Woman with Breast Cancer May Have Saved Her Twin’s Life by... 16 Οκτωβρίου, 2020 Coping With the Holidays During COVID-19 and Cancer 24 Νοεμβρίου, 2020 Aromatase inhibitors cut breast cancer recurrence in younger patients 11 Φεβρουαρίου, 2022 Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... 7 Απριλίου, 2025 Φόρτωση περισσοτέρων HOT NEWS The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... How to Strengthen Your Immune System: Part 1 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients...